Grand Pharmaceutical Launches UI-SEEK for Early Tumor Detection in China

Grand Pharmaceutical Group Limited ( (HK:0512) ) has issued an update.

Grand Pharmaceutical Group Limited has announced the first commercial prescription of UI-SEEK, an early detection product for urinary system tumors, in Mainland China. This product, developed with AcornMed, is the first of its kind in China to use a dual mechanism of methylation and gene mutation for non-invasive tumor diagnosis. The company aims to strengthen its market position in urological tumor diagnosis and expand its product portfolio to meet clinical needs in early detection and treatment of various cancers.

More about Grand Pharmaceutical Group Limited

Grand Pharmaceutical Group Limited is a company involved in the nuclear medicine anti-tumor diagnosis and treatment industry. It collaborates with AcornMed Biotechnology Co., Ltd. to develop products for early tumor detection and precision medical testing, focusing on unmet clinical needs in cancer diagnosis and treatment.

YTD Price Performance: 27.72%

Average Trading Volume: 9,351,944

Technical Sentiment Signal: Sell

Current Market Cap: HK$20.8B

For an in-depth examination of 0512 stock, go to TipRanks’ Stock Analysis page.